143 related articles for article (PubMed ID: 35965073)
1. Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases.
Kaneko K; Shikano K; Kawazoe M; Kawai S; Nanki T
Intern Med; 2022; 61(16):2405-2415. PubMed ID: 35965073
[TBL] [Abstract][Full Text] [Related]
2. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
3. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
Suzuki T; Nakamura Y; Kato H
Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.
Tamechika SY; Ohmura SI; Maeda S; Naniwa T
J Bone Miner Metab; 2023 Mar; 41(2):203-211. PubMed ID: 36512086
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
7. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
8. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
[TBL] [Abstract][Full Text] [Related]
9. Effects of denosumab treatment in chronic liver disease patients with osteoporosis.
Saeki C; Saito M; Oikawa T; Nakano M; Torisu Y; Saruta M; Tsubota A
World J Gastroenterol; 2020 Sep; 26(33):4960-4971. PubMed ID: 32952342
[TBL] [Abstract][Full Text] [Related]
10. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
[TBL] [Abstract][Full Text] [Related]
11. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
[No Abstract] [Full Text] [Related]
13. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
14. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
[TBL] [Abstract][Full Text] [Related]
15. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
[TBL] [Abstract][Full Text] [Related]
16. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
[TBL] [Abstract][Full Text] [Related]
17. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
[TBL] [Abstract][Full Text] [Related]
18. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
[TBL] [Abstract][Full Text] [Related]
20. Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.
Hori M; Yasuda K; Takahashi H; Kondo C; Shirasawa Y; Ishimaru Y; Sekiya Y; Morozumi K; Maruyama S
Sci Rep; 2022 May; 12(1):7781. PubMed ID: 35546172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]